Drug
Tazarotene (GRI-0621)
Status:
Phase 2
Condition:
Idiopathic Pulmonary Fibrosis
Intervention Type:
Oral Drug
Funder Type:
Industry
Drug Details
Tazarotene (GRI-0621) is an oral therapy that suppresses natural killer T-cells (iNKT cells) and normalizes cellular differentiation, which halts the inflammatory pathways that drive progressive lung scarring.
Study Purpose
This drug has no clinical trials actively recruiting patients at this time.